Autor(es): Winer J B

Resumo: Most patients with Guillain-Barré syndrome (GBS) respond to treatment with intravenous immunoglobulin, but it is not uncommon for some to continue to deteriorate for a period after treatment has been started. This may reflect the natural history of the disease, or an error in diagnosis. This article reflects my own view of what to do in this situation, with a review of what few data there are to guide decision making.

Imprenta: Practical Neurology, v. 9, n. 4, p. 227-230, 2009

Identificador do objeto digital: 10.1136/jnnp.2009.176578

Descritores: Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Immunology

Data de publicação: 2009

INDICADORES

ACESSO